In vivo studies showed that the combination of IP administration and the use of targeted HBc particles (99mTc-ZHER2-ΔHBc) resulted in significantly enhanced tumour accumulation in the intraperitoneal tumour model, suggesting selective uptake of ZHER2-ΔHBc particles in HER2 (+++) tumours in vivo. Findings from this work offer fundamental knowledge on the biodistribution of newly reported recombinant HBc particles designed for local delivery of nucleic acids to intraperitoneal cancer. This evidence concerns the gene KRT88P and cancer.